INFO: EASL 2007 42st Meeting of the European Association for the Study of Liver Diseases Conference Reports

[Guest guest]

Conference Reports for NATAP EASL42st Meeting of the European Association for the Study of Liver DiseasesApril 11-15, 2007Barcelona, Spain Pegasys vs Peg/ADV for Hepatitis D Virus: Pegasys most effective - (05/03/07) HCV Antiviral Activity and Resistance Analysis in

Chronically Infected Chimpanzees Treated with Merck NS3/4A Protease and NS5B Polymerase Inhibitors - (05/03/07) Low-Dose PegIFN Maintenance Therapy Successful - (05/03/07) Influence of ARTs in the Progression of Liver Fibrosis in HCV/HIV Coinfected Patients: effect of hepatoxicity and metabolic abnormalities - (05/01/07) Insulin Resistance Causes Fibrosis - (05/01/07) Tenofovir + 3TC or FTC Efficacy in HBV/HIV Coinfection: 85% <1000 IU/ml - (05/01/07) Albuferon Once Every 2 or 4 Weeks Interferon Looks Good in Phase 2 Study - (05/01/07) Inherited Variants of Genes Involved in Insulin Signaling and Lipogenesis Influence The Risk of Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease - (05/01/07) Insulin Resistance in HBV, HCV & Non-Virus Related Chronic Hepatitis (liver enzymes) - (05/01/07) Insulin Resistance Inflames The Liver in HCV - (05/01/07) Insulin Resistance in 424 HCV+ Patients: association with HCV replication and advanced fibrosis -

(05/01/07) Statins May Improve Liver Fibrosis - (05/01/07) PegIntron + 2 HCV Nucleosides Show Synergy - (04/27/07) R1479 (R1626), a Novel Hepatitis C Polymerase Inhibitor: Lack of Pre-Existing Resistance Mutations Supports the Observed In Vivo High Barrier to Resistance - (04/27/07) ITMN-191 CONCENTRATIONS ACHIEVED IN THE LIVER OF ANIMALS PROMOTE HCV REPLICON CLEARANCE IN VITRO AND THIS EFFECT IS ENHANCED BY PEG-IFN a-2a (Pegasys) - (04/27/07) HCV

Protease Inhibitor ITMN-191 Resistance - (04/27/07) HCV Protease Inhibitor ITMN-191 + HCV Polymerase Inhibitor R1626 Synergy - (04/27/07) Lipid steatosis, metabolic variables and body composition in the setting of HIV/HCV coinfection; findings from a large randomised trial (APRICOT) - (04/26/07) 400,000 IU/mL Is New Cut-Off for Low vs High Viral Load in HCV - (04/26/07) Favorable Cross-Resistance Profile of Two Novel Hepatitis C Virus Inhibitors, SCH 503034 (Boceprevir) and HCV-796, and Enhanced Anti-Replicon Activity Mediated by the Combined Use of

Both Compounds - (04/26/07) SCH503034 & NM283 Not Cross-Resistant - (04/26/07) An open label, comparative, multi-center study of peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin in the treatment of patients with chronic hepatitis C/hepatitis B dual infection versus with mono-infected chronic hepatitis C: An interim report - (04/25/07) Virological response at 4 and 12 weeks predict high rates of sustained virological response in genotype 1 patients treated with peginterferon alfa-2a (40KD) plus ribavirin - (04/25/07) EFFECTS OF INSULIN

SENSITIZING AGENTS IN NONALCOHOLIC FATTY LIVER DISEASE, METABOLICS: metformin, rosiglitazone, metformin+rosiglitazone - (04/23/07) In vitro Resistance Selection to the HCV Nucleoside Polymerase Inhibitor R1479 (R1626) and to the Protease Inhibitor VX-950 - (04/23/07) SVR Durable (99%) After 5 Years of Followup - (04/23/07) 48 Weeks & High Ribavirin Dose May Improve SVR Rates for Genotype 2/3, French study by Bernard Willems - (04/23/07) In Patients Who Clear HCV RNA At Week 12 (between week 8 and 12): SVR is Higher After 72 Weeks Than After 48 Weeks

Treatment: Results of a Randomized Controlled Trial - (04/23/07) New HCV Drug Target NS4A Antagonists - (04/23/07) 76 Week Follow-up of HBeAg-Positive Chronic Hepatitis B Patients Treated with Telbivudine, Adefovir or Switched from Adefovir to Telbivudine - (04/23/07) HBV rtI233V Polymerase Variant Remains Sensitive to Adefovir - (04/23/07) Pegasys Superior to Lamivudine Over 3 Years in HBV DNA Decline, ALT Normalization & HBsAg Loss (8% vs 0) & Seroconversion (4% vs 0) - (04/23/07) Peginterferon a-2a Plus adefovir vs Peginterferon a-2a for 48 Weeks in HBeAg-Negative Chronic Hepatitis B: Preliminary 24-Week Results of the PEG FOR B Randomized Multicenter Trial - (04/23/07) 3 YEARS OF ADEFOVIR AND LAMIVUDINE COMBINATION THERAPY MINIMIZES THE RISK OF GENOTYPIC RESISTANCE TO ADV IN LAM RESISTANT PATIENTS - (04/20/07) 14 Weeks vs 24 Weeks Peg/RBV for Genotypes 2/3 - (04/20/07) CANNABIS USE AS AN INDEPENDENT PREDICTOR OF SEVERE STEATOSIS DURING CHRONIC HEPATITIS C - (04/19/07) Efficacy

of Entecavir and Lamivudine in Chronic Hepatitis B Patients with Advanced Liver Fibrosis/Cirrhosis - (04/19/07) Presence of Biopsy-Proven Histologic Damage (Necroinflammation and Fibrosis) is Common even when ALT is less than 2 X ULN in Patients with Chronic Hepatitis B - (04/19/07) Abbott HCV Polymerase Inhibitor - (04/18/07) 3-Drug HCV therapy for 12 weeks: VX950+pegIFN+RBV, interim results from phase II PROVE 1 Trial - (04/17/07) HCV-796 Polymerase Inhibitor Shows 1.5 log Viral Load Reduction - (04/17/07) GSK625433: A Novel and Highly potent Inhibitor of the HCV NS5B Polymerase - (04/17/07) Merck HCV Protease & Polymerase Inhibitor Viral Load Reduction & Resistance in Chimps - (04/17/07) GSK625433: A Novel and Highly Potent Inhibitor of the HCV NS5B Polymerase - (04/17/07) Interim Results Presented at EASL from PROVE 1 Clinical Trial of Investigational Drug Telaprevir in Patients with Genotype 1 Hepatitis C - (04/17/07) New HCV Drug Target NS4A Antagonists - (04/17/07) Entecavir (ETV) Results in Higher HBV-DNA Reduction vs Adefovir (ADV) in Chronically Infected HBeAg(+) Antiviral-Naive Adults: 48-Wk Results (E.A.R.L.Y. Study) - (04/17/07) Four Year Assessment Of Entecavir Resistance In Nucleoside Naive and Lamivudine Refractory Patients - (04/17/07) Four-Year Data Demonstrate Continued Low Incidence of BARACLUDE (entecavir) Resistance in Nucleoside-naive Chronic Hepatitis B Patients (press release from BMS) - (04/17/07) BARACLUDE (entecavir) Therapy Resulted in Undetectable Levels of Hepatitis B Virus in Cohort of Patients

Who Re-Started Treatment (press release from BMS) - (04/17/07) ETV Re-treatment of Nucleoside-Naive HBeAg(-) Patients with Recurrent Viremia - (04/17/07) NM283 in Treatment-Naives Looks Better - (04/13/07) NM283, HCV Polymerase Inhibitor in Non-Responders - (04/13/07) Resistance to New HCV Antivirals - (04/12/07) Vertex Pharmaceuticals Announces New Data for Investigational HCV Protease Inhibitor Telaprevir to be Presented at 42nd Annual Meeting of

the European Association for the Study of the Liver (EASL) - (04/12/07) New Clinical Study Results Indicate Higher Early Virologic Response with Celgosivir Combination Therapy in HCV Non-Responders - (04/12/07)